Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study

Casal, J.; Amenedo, Margarita; Mel, J. R.; Antón, L. M.; Rodríguez-López, Rubén; López‐López, Rafael; González-Ageitos, A.; Castellanos, Jorge; Constenla, Manuel; Tisaire, J.

doi:10.1007/s00280-007-0418-7

Cited by 7 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The every-3-week schedules used consist of docetaxel 75–100 mg/m 2 on day 1 or day 8 and gemcitabine 900–1000 mg/m 2 on days 1 and 8. Response rates of 26–50% and a median overall survival of 7–13 months have been reported in phase II trials [ 19 - 23 ].…”

Section: Discussionmentioning

confidence: 99%

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer

et al. 2008

View full text Add to dashboard Cite

show abstract

“…The remaining 314 records dealt with the LC13; however, of these, 74 records were excluded because they did not present original data obtained by means of the module. Consequently, n = 240 articles were considered clinical studies according to our definition and were included in further analyses …”

Section: Resultsmentioning

confidence: 99%

Use of the lung cancer–specific Quality of Life Questionnaire EORTC QLQ‐LC13 in clinical trials: A systematic review of the literature 20 years after its development

Koller

Warncke

Hjermstad

et al. 2015

Cancer

View full text Add to dashboard Cite

13 (QLQ-LC13) covers 13 typical symptoms of lung cancer patients and was the first module developed in conjunction with the EORTC core qualityof-life (QL) questionnaire. This review investigates how the module has been used and reported in cancer clinical trials in the 20 years since its publication. Thirty-six databases were searched with a prespecified algorithm. This search plus an additional hand search generated 770 hits, 240 of which were clinical studies. Two raters extracted data using a coding scheme. Analyses focused on the randomized controlled trials (RCTs). Of the 240 clinical studies that were identified using the LC13, 109 (45%) were RCTs. More than half of the RCTs were phase 3 trials (n 5 58). Twenty RCTs considered QL as the primary endpoint, and 68 considered it as a secondary endpoint. QL results were addressed in the results section of the article (n 5 89) or in the abstract (n 5 92); and, in half of the articles, QL results were presented in the form of tables (n 5 53) or figures (n 5 43). Furthermore, QL results had an impact on the evaluation of the therapy that could be clearly demonstrated in the 47 RCTs that yielded QL differences between treatment and control groups. The EORTC QLQ-LC13 fulfilled its mission to be used as a standard instrument in lung cancer clinical trials. An update of the LC13 is underway to keep up with new therapeutic trends and to ensure optimized and relevant QL assessment in future trials.

show abstract

“…ORR , TTP, and OS were 20.4%, 3.6 months, 8.7 months respectively in DG arm versus 31.0%, 5.2 months, 9.4 months, respectively in arm Cis-Gem+Doc (P>0.05). Similarly, the other five phase II trials [17][18][19][20][21] reported no statistical difference in survival between the two regimens.…”

Section: Toxicitymentioning

confidence: 91%

Gemcitabine-docetaxel versus gemcitabine - cisplatin as first-line therapy in patients with advanced non-small cell lung cancer

Algizawy

Mostafa

2014

Kasr-Al-Aini J.of Clin. Onc. and Nuc. Med.

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer deaths worldwide in men, and second most common in women. Worldwide, lung cancer occurred in approximately 1.8 million patients in 2012 and caused an estimated 1.6 million deaths 1. Non-small-cell lung cancer (NSCLC) represents more than 80% of lung cancer diagnoses and has an overall 5-year survival rate of approximately 16%, which decreases precipitously among patients diagnosed with late stage disease 2. Despite enthusiasm for the use of molecular testing and molecularly targeted agents in patients with advanced non-small cell lung cancer (NSCLC), most patients are not candidates for upfront treatment with molecular agents. Moreover, many candidate patients can't afford the vastly increased cost of such novel agents. Chemotherapy therefore remains the first-line treatment for most patients with stage IV non-small cell lung cancer (NSCLC) 3. Multiple individual randomised studies and several meta-analyses have shown a survival benefit for platinumbased chemotherapy compared with best supportive care in patients with good performance status 4,5 , but at the cost of severe toxicities. Combinations with better toxicity profile but with equal or improved efficacy are eagerly needed. Nonplatinum combinations have been tested and are considered alternative regimens for those who cannot tolerate platinum-based chemotherapy. Among these combinations, the combination of gemcitabine and docetaxel has emerged as one of the most promising, showing equivalent efficacy with, and less toxicity than, cisplatin-based chemotherapies 6 .

show abstract

Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study

Abstract: Gemcitabine 1,000 mg/m(2) on days 1 and 8 in combination with docetaxel 85 mg/m(2) on day 8 given in 3-week cycles is an active and well-tolerated first-line chemotherapeutic regimen for advanced NSCLC.

Cited by 7 publications

References 25 publications

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer

Use of the lung cancer–specific Quality of Life Questionnaire EORTC QLQ‐LC13 in clinical trials: A systematic review of the literature 20 years after its development

Gemcitabine-docetaxel versus gemcitabine - cisplatin as first-line therapy in patients with advanced non-small cell lung cancer

Contact Info

Product

Resources

About